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ABSTRACT 
Vascular adhesion of circulating tumor cells (CTCs) is a key step in cancer spreading. If inflammation is 
recognized to favor the formation of vascular ‘metastatic niches’, little is known about the contribution 
of blood rheology to CTC deposition. Herein, a microfluidic chip, covered by a confluent monolayer of 
endothelial cells, is used for analyzing the adhesion and rolling of colorectal (HCT-15) and breast (MDA 
MB-231) cancer cells under different biophysical conditions. These include the analysis of cell transport 
in a physiological solution and whole blood; over a healthy and a TNF-a inflamed endothelium; with a 
flow rate of 50 and 100 nL/min. Upon stimulation of the endothelial monolayer with TNF-a (25 ng/mL), 
CTC adhesion increases by 2 to 4 times whilst cell rolling velocity only slightly reduces. Notably, whole 
blood also enhances cancer cell deposition by 2 to 3 times, but only on the unstimulated vasculature. For 
all tested conditions, no statistically significant difference is observed between the two cancer cell types. 
Finally, a computational model for CTC transport demonstrates that a rigid cell approximation 
reasonably predicts rolling velocities while cell deformability is needed to model adhesion. These results 
would suggest that, within microvascular networks, blood rheology and inflammation contribute 
similarly to CTC deposition thereby facilitating the formation of metastatic niches along the entire 
network, including the healthy endothelium. In microfluidic-based assays, neglecting blood rheology 
would significantly underestimate the metastatic potential of cancer cells. 
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INTRODUCTION 
The formation of distant metastasis from a primary neoplastic mass is a very inefficient biological 
process.(Talmadge and Fidler 2010; Nguyen, Bos, and Massague 2009; Wirtz, Konstantopoulos, and 
Searson 2011; Joyce and Pollard 2009) Spreading of cancer cells evolves following a precise cascade of 
events – the metastatic cascade – requiring cell migration away from the primary mass and intravasation 
into blood or lymphatic vessels, following the epithelial to mesenchymal transition; circulation within 
the blood stream, where cells have to survive hemodynamic stresses and immune cell recognition; 
extravasation, migration and proliferation at the secondary sites. Radioactive assays documented that 
only 1% of circulating tumor cells (CTCs) can successfully overcome all these sequential steps and 
eventually establish distant metastases.(Fidler 1970) Despite the inefficiency and complexity of the 
process, the vast majority of cancer patients who relapse eventually succumb because of metastases, 
disseminated at different secondary sites, rather than for the uncontrolled growth of the original 
malignancy.(Chaffer and Weinberg 2011)  
 
CTC arrest within different vascular districts is a key step in the metastatic cascade and is primarily 
mediated by two mechanisms: vascular occlusion, which generally occurs in the small capillary beds of 
the brain and lungs(Kienast et al. 2010); and vascular adhesion, which is regulated by specific 
interactions between receptor molecules on the endothelium and ligand molecules on CTCs.(Schluter et 
al. 2006; Witz 2008) A wide range of vascular molecules are involved in this specific adhesion process, 
including E- and P-selectins, avb3 and avb5 integrins, VCAM-1 and ICAM-1 adhesion 
molecules.(Burdick et al. 2003; Barthel et al. 2007; Myung et al. 2011) These receptors can bind several 
different ligands expressed on the CTC membrane, making target therapies against metastasis practically 
impossible. This picture is further complicated by the fact that platelets, leukocytes and CTCs tend to 
form in the circulation stable aggregates that favor blood longevity and vascular deposition of malignant 
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cells.(Gay and Felding-Habermann 2011; Borsig et al. 2002) In this context, pro-inflammatory 
cytokines(Solinas et al. 2010; Kim et al. 2009), such as TNF-a, IL-1b and IL-6; tumor-derived 
exosomes(Hoshino et al. 2015; Hood, San, and Wickline 2011) and hematopoietic cells(Kaplan et al. 
2005; Shiozawa et al. 2011) have been shown to modulate the expression of adhesion molecules in 
specific vascular districts thus priming the formation of so called ‘pre-metastatic niches’ where CTCs 
more efficiently, and in a larger number, accumulate.  
 
Cell-cell adhesion is strongly modulated by external forces and, as such, static assays may not always 
reproduce the complex interactions developing under flow within the vasculature. Intravital microcopy 
has been extensively employed to document cell migration within vascular and extravascular 
compartments,(Kienast et al. 2010; Provenzano, Eliceiri, and Keely 2009) however these in vivo analyses 
lack a precise control on the governing parameters. On the other hand, microfluidic chips allow to 
precisely control blood vessel sizes, flow rates and the expression of vascular adhesion molecules and 
are amenable for high through-put systematic characterizations. A variety of microfluidic chips are being 
developed for studying the different steps in the metastatic cascade. For instance, the group of Kamm 
designed flow devices for assessing transvascular migration of cancer cells in different extravascular 
matrices.(Bersini et al. 2014; Jeon et al. 2015; Niu et al. 2014; Zervantonakis et al. 2012) The vascular 
adhesion and transmigration of individual and clustered CTCs was studied under chemokine stimulation 
(exposure to CXCL12 and SDF-1a) by various groups.(Song et al. 2009; Zhang, Liu, and Qin 2012; 
Roberts, Waziri, and Agrawal 2016) Studies of cancer cell migration within the lymphatic system were 
presented by Swartz and collaborators.(Pisano et al. 2015) The group of Jiang focused on investigating 
the role of endothelial cell mechanical (cyclic shear stresses) and biochemical (exposure to TNF-a) 
stimulation on CTC vascular adhesion.(Huang et al. 2015) Huang and collaborators developed cellulose-
5 
 
based tubular artificial blood vessels for reproducing the intravasation, vascular adhesion and 
extravasation of cancer cells.(Wang et al. 2015)  
 
Although red blood cells (RBCs) are known to affect the dynamics of leukocytes and CTCs, at authors’ 
knowledge, no studies have addressed the relative roles of vascular inflammation and RBC dynamics on 
the vascular deposition of malignant cells. In this work, a microfluidic chip is used to study the rolling 
and firm adhesion of breast (MDA-MB-231) and colorectal cancer (HCT-15) cells on a confluent layer 
of human vascular endothelial cells (HUVECs). The hematocrit of the working solution ranges from 0 
to 40% and TNF-a is used for stimulating HUVECs. The rolling velocity and number of firmly adhering 
tumor cells are measured under different conditions. A Lattice-Boltzmann computational model is also 
included to interpret and reproduce the vascular adhesion dynamics of cells. 
 
RESULTS AND DISCUSSIONS 
A continuously growing body of evidence documents that vascular inflammation supports the firm 
adhesion of circulating tumor cells (CTCs) and facilitate the distant colonization of otherwise healthy 
tissues with the consequent formation of tumor metastases.(Solinas et al. 2010; Kim et al. 2009; Hoshino 
et al. 2015; Hood, San, and Wickline 2011) In this context, human vascular endothelial cells (HUVECs) 
were stimulated with the pro-inflammatory cytokine TNF-α and the adhesion propensity of cancer cells 
(HCT-15 and MDA-MB-231) was assessed under static and dynamic conditions. The two cell lines are 
among the most metastatic and aggressively growing colon and breast cancer cells, 
respectively.(Flatmark et al. 2004; Holliday and Speirs 2011) 
 
Cancer cell adhesion on inflamed endothelial cells under dynamic conditions. HUVECs were seeded 
in multiwell plates and, after reaching confluency, were stimulated with TNF-α (10 ng/mL, 25 ng/mL 50 
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ng/mL) for 6 hours. Cancer cells were added to the multiwell plates and left interacting with the 
endothelial cells up to 4 hours, under static conditions. In agreement with a large body of literature, these 
static experiments continue to confirm that endothelial stimulation with a pro-inflammatory cytokine 
(TNF-α) favors CTC vascular adhesion in a dose dependent manner (Supporting Figure.1 and 2). 
Moving from static to dynamic experimental conditions, a PDMS single-channel microfluidic chip was 
used for monitoring the interaction of cancer and endothelial cells under flow (Figure.1a). The 
microfluidic channel was 2.7 cm long and had a 210 µm wide by 42 µm high rectangular cross section. 
The working fluid was introduced in the PDMS chip continuously for about 15 minutes at two different 
flow rates, namely 50 and 100 nL/min. These flow rates reproduce wall shear rates (13.49 and 26.99 s-1) 
and mean blood velocities (94.48 and 188.9 µm/s) typically found in the microcirculation.(Popel and 
Johnson 2005)  The PDMS channel was covered by a confluent layer of endothelial cells mimicking the 
blood vessel walls; whereas the cancer cells were dispersed within the working fluid consisting of either 
cell culture media or whole blood. Again, two different malignant cell lines were considered, namely 
colon (HCT-15) and breast cancer (MDA-MB-231) cells. In order to reproduce an inflamed endothelium, 
the HUVEC monolayer was stimulated with the pro-inflammatory cytokine TNF-α. Representative 
confocal fluorescent images of the experimental set-up with cells are shown in Figure.1b. Red 
fluorescent cancer cells (CM-DIL staining of the membrane) are spotted firmly adhering over blue 
fluorescent HUVECs (DAPI staining of the nucleus). The same images show in green VE-cadherin 
molecules decorating the boundary between two adjacent endothelial cells and demonstrating the high 
level of confluency of the endothelial monolayer deposited on the microfluidic channel surface. 
 
Via fluorescent microscopy, the number of adhering cells was quantified, within five different regions 
of interest (ROIs) along the channel, and normalized by the total number of injected cells (ninj =106) and 
the ROI area. This was performed for twelve different working conditions depending on the types of 
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cancer (colon and breast); flow rates (50 and 100 nL/min) and levels of HUVEC inflammation (un-
stimulated: -TNF-a; 6 hours stimulation: +TNF-a 6h; and 12 hours stimulation: +TNF-a 12h). Results 
are provided in Figure.2b and d, respectively, for a flow rate Q = 50 and 100 nL/min, and for breast 
cancer (blue bars) and colon cancer (red bars) cells. On the left hand side, Figure.2a and c, representative 
fluorescent microscopy images are shown for unstimulated, 6 hour stimulated, and 12 hour stimulated 
HUVECs. These images are snapshots taken from full movies available as Supporting Information. 
Notably, for all twelve different working conditions, no statistically significant difference was depicted 
when comparing breast and colon cancer cells. Conversely, significant differences arose when 
considering different flow rates and levels of TNF-a stimulation. At Q = 50 nL/min, the normalized 
number of adhering HCT-15 and MDA-MB-231 cells was, respectively, 9.952 ± 1.803 and 10.24 ± 2.841 
#/m2 in control experiments, 29.09 ± 2.219 and 28.54 ± 5.038 #/m2 after 6 hours of TNF-a stimulation; 
40.37 ± 9.205 and 40.26 ± 3.521 #/m2 after 12 hours of TNF-a stimulation. At Q = 100 nL/min, the 
normalized number of adhering HCT-15 and MDA-MB-231 cells was, respectively, 6.698 ± 1.452 and 
7.30 ± 1.088 #/m2 in control experiments, 11.87 ± 0.899 and 13.78 ± 1.716 #/m2 after 6 hours of TNF-a 
stimulation; 34.05 ± 1.427 and 26.69 ± 2.780 #/m2 after 12 hours of TNF-a stimulation.  
As compared to the healthy vasculature, cancer cells adhered 2 and 3-times more avidly to a 6h- and 12h-
inflamed endothelium. Maximum cell adhesion is observed under static conditions (Q = 0, Supporting 
Figure.1c), followed by Q = 50 and 100 nL/min. Thus, as expected, the number of adhering cells reduces 
as the flow rate increases. Indeed, this is related to the corresponding increase of the hydrodynamic 
dislodging forces that would decrease the likelihood of firm CTC adhesion on HUVECs.  
 
Cancer cell rolling on inflamed endothelial cells under dynamic conditions.  A subset of circulating 
tumor cells was observed to interact with the endothelial monolayer without firmly adhering but rather 
rolling steadily. The cancer cells exposed to a dynamic conditions are transported within the microfluidic 
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chip at two different flow rates (50 and 100 nL/min). The solution is injected into the microfluidic chip 
using a syringe pump for 15 minutes Thus, the rolling velocity uroll of tumor cells was quantified by 
monitoring the displacement of the cell centroid over time. Movies for rolling cells are provided in the 
Supporting Information under different flow rates, HUVEC inflammation levels and cell types. By 
imaging post-processing, uroll of the metastatic colon (HCT-15) and breast (MDA-MB-231) cancer cells 
was quantified at 50 and 100 nL/min, and under different HUVEC conditions, namely unstimulated 
HUVECs (- TNF-α), 6h-stimulated HUVECs (+TNF-α 6h), and 12h-stimulated HUVECs (+TNF-α 12h). 
Data are charted in Figure.3a and b, respectively, for 50 and 100 nL/min. At 50 nL/min, the rolling 
velocity of HCT-15 cells was of 113.9 ± 4.132, 103.4 ± 2.880 and 98.00 ± 4.552 µm/sec for unstimulated 
HUVECs (- TNF-α), 6h-stimulated HUVECs (+TNF-α 6h), and 12h-stimulated HUVECs (+TNF-α 12h), 
respectively. Under the same conditions, for the MDA-MB-231, the rolling velocities were 118.6 ± 1.349 
µm/sec 105.68 ± 3.340 µm/sec 102.1 ± 5.288 µm/sec (Figure.3a). Even in the case of rolling velocities, 
no statistically significant difference was observed between the two cell lines. A 10% and 20% 
statistically significant decrease in rolling velocities between the control groups and the 6 and 12 hours 
TNF-α stimulated groups was observed. Under TNF-a stimulation, endothelial cells express a larger 
number of adhesion molecules, which would reduce the rolling velocity and favor the firm deposition of 
CTCs. Note that, this is in agreement with what was documented by Navarro and collaborators (Ríos-
Navarro et al. 2015) in the case of polymorphonuclear (PMNCs) and peripheral blood mononuclear 
(PBMCs) cells. 
As expected, the rolling velocity slightly but steadily decreased as the level of TNF-α stimulation 
increased. At 100 nL/min, the rolling velocities for the HCT-15 cells were 163.6 ± 20.10 µm/sec (-TNF-
α), 157.4 ± 4.531 µm/sec (TNF-α 6h) and 158.06 ± 1.187 µm/sec (TNF-α 12h). For the MDA-MB-231, 
the same physical quantity took the values 170.9 ± 11.03 µm/sec (-TNF-α); 151.8 ± 8.182 µm/sec (6h 
TNF-α) and 144.9 ± 1.500 µm/sec (12h TNF-α).  
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Lastly, the ratio between the number of rolling and adhering cells was plotted for two different flow 
conditions (Figure.3c and d). For unstimulated HUVECs, most of the circulating tumor cells were 
observed to steadily roll over the endothelium monolayer, whereas the ratio decreases as the TNF-α 
stimulation increases. At low flow rates (Q = 50 nL/min), the ratio for the HCT-15 cells was 0.845 ± 
0.084 (-TNF-α); 0.713 ± 0.122 (TNF-α 6h) and 0.553 ± 0.096 (TNF-α 12h). Very similar are the ratios 
quantified for the MDA-MB-231, for which it resulted 0.828 ± 0.067 (- TNF-α), 0.669 ± 0.034 (TNF-α 
6h) and 0.597 ± 0.030 (TNF-α 12h). At high flow rates (Q = 100 nL/min), the ratio for the HCT-15 cells 
was 0.875 ± 0.020 (- TNF-α), 0.728 ± 0.038 (TNF-α 6h) and 0.591 ± 0.017 (TNF-α 12h). Similarly, for 
the MDA-MB-231, the ratio was 0.850 ± 0.061 (- TNF-α), 0.715 ± 0.015 (TNF-α 6h) and 0.651 ± 0.063 
(TNF-α 12h). As reported before for other physical quantities, also in this case, no statistically significant 
difference was determined between the two cell lines. 
 
Cancer cell adhesion on inflamed endothelial cells under whole blood flow. Leukocyte recruitment 
at inflamed tissues has a number of similarities with the colonization at distant sites of CTCs. In 
particular, just like for leukocytes, CTCs tend to transiently interact with the blood vessel walls engaging 
specific receptor molecules, then adhere and spread over the endothelial cells and, eventually, cross the 
vascular barrier relocating in the extravascular space. Adhesion molecules are over-expressed in 
postcapillary venules during an inflammatory process.(Granger and Senchenkova 2010; Strell and 
Entschladen 2008; McEver and Zhu 2010). Moreover, it is well recognized that leukocyte rolling and 
adhesion on the inflamed vascular endothelium is modulated by the presence of red blood cells (RBCs). 
Specifically, experimental observation and simulations have shown that the deformability and shape of 
RBCs allow them to concentrate within the core of blood vessels leaving a so-called ‘cell free layer’ next 
to the vessel walls.(Goldsmith, Cokelet, and Gaehtgens 1989; Pappu and Bagchi 2007; Fedosov, 
Noguchi, and Gompper 2014; Firrell and Lipowsky 1989) Leukocytes, which are two-times larger and 
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far less abundant than RBCs, tend to be pushed laterally in the cell free layer by the fast moving RBCs. 
This process, known as ‘margination’, should also affect the vascular behavior of CTCs. 
 
In this section, cancer cell rolling and adhesion over a monolayer of HUVECs is analyzed in the presence 
of whole blood. The single-channel microfluidic chip was again covered by a confluent monolayer of 
HUVECs, which were unstimulated or stimulated with TNF-α (12h only), and cancer cells re-suspended 
in whole blood were directly injected at two different flow rates (Q = 50 and 100 nL/min). Whole blood, 
freshly drawn from rats, contained all the cell and molecular components of blood, including red blood 
cells, platelets, leucocytes and plasma proteins which may all contribute, at different extents, to cancer 
cell rolling and adhesion.(Gay and Felding-Habermann 2011; Borsig et al. 2002) A fixed hematocrit of 
40% was considered. Results for eight different working conditions are provided in Figure.4b and d, 
which are for Q = 50 and 100 nL/min, respectively. As previously, breast cancer cells are identified by 
blue bars whereas colon cancer cells are associated with red bars. On the left hand side (Figure.4a and 
c), representative fluorescent microscopy images are shown for unstimulated HUVECs (- TNF-α), and 
12h-stimulated HUVECs (+TNF-α 12h). The results unequivocally showed that blood cells favor the 
adhesion of circulating tumor cells to the vascular walls, especially in the case of unstimulated 
endothelium. In Figure.4b and d, the normalized number of adhering cells is reported. At Q = 50 nL/min, 
the normalized number of adhering HCT-15 and MDA-MB-231 cells was 25.33 ± 4.762 and 18.19 ± 
1.269 #/m2 in control experiments, 35.68 ± 10.99 and 46.96 ± 13.18 #/m2 after 12 hours of TNF-a 
stimulation, respectively. At  Q =100 nL/min, the normalized number of adhering HCT-15 and MDA-
MB-231 cells was 26.04 ± 9.90 and 17.59 ± 6.129 #/m2 in control experiments, 30.12 ± 4.011 and 23.04 
± 4.406 #/m2 after 12 hours of TNF-a stimulation, respectively. Notably, even under these conditions, 
no statistically significant difference in cell adhesion was detected between breast and colon cancer cells. 
Interestingly, a statically significant difference was measured only between untreated and TNF-a treated 
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endothelial cells at the lowest flow rate (Q = 50 nL/min, in Figure.4b). At highest flow rates, the absolute 
number of adhering cells reduces and twelve hours TNF-a stimulation is insufficient to induce a 
statistically significant increase in cell deposition.  
 
A direct comparison in terms of CTC vascular adhesion between whole blood flow and physiological 
solution is now needed. Figure.4e and f collect all the data required for this comparison. Within an 
unstimulated microvascular network, the presence of blood cells does dramatically increase CTC 
adhesion (Figure.4e). For Q = 50 nL/min, the density of firmly adhering CTCs grows from about 10 to 
20 #/m2 moving from physiological solution to whole blood flow. A slightly larger increase is observed 
for Q = 100 nL/min. Differently, within an inflamed microvascular network, the presence of blood cells 
does not significantly affect CTC adhesion (Figure.4f). The density of firmly adhering CTCs is around 
40 #/m2 at 50 nL/min and reduces to about 30 #/m2 at 100 nL/min, with and without RBCs. This could 
be interpreted as, under the current conditions, the density of adhering CTCs on the inflamed endothelium 
has reached saturation and the presence of RBCs cannot further foster cell deposition. Also, RBC-CTC 
collisions could limit any further increase in cell deposition. Indeed, additional experiments would be 
needed to support this hypothesis. Interestingly, a direct comparison of the data presented in Figure.4e 
and f would lead one to infer that, at higher flow rates (100 nL/min), the density of firmly adhering CTCs 
on the inflamed and normal vasculature is comparable when a whole blood flow is considered. Again, 
this could be due to a balance between shear stresses and cell-cell collisions. Indeed, this is not observed 
at low flow rates (50 nL/min), where adhesion is higher on inflamed endothelium. 
 
This data confirms that blood cells facilitate the vascular adhesion of CTCs, just like for leukocytes, and 
open up to the following two considerations: CTCs would tend to adhere throughout the 
microvasculature, on both inflamed and not inflamed endothelial cells, thus increasing the likelihood of 
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finding proper conditions for colonization; in microfluidic experiments, neglecting the role of blood cells 
could dramatically underestimate the adhesion propensity of CTCs.  
 
Predicting cancer cell adhesion and rolling on inflamed endothelial cells. In order to predict CTC 
vascular behavior under different flow and adhesion conditions, a computational model was employed 
based on previous works by the authors.(Decuzzi and Ferrari 2006; Coclite et al. 2016; Coclite et al. 
2017) In this model, cancer cells were considered as rigid and deformable circular objects exposed to a 
Poiseuille flow and capable of interacting with vascular walls (endothelial cells) via specific ligand-
receptor bonds (Figure.5a). Simulations were performed in a rectangular computational domain, with 
height H (= 42 µm) and length 10H, resembling the longitudinal cross section of the single channel in 
the microfluidic chip. The diameter of cancer cells was fixed to d= 15 µm, as quantified via bright field 
microscopy (Supporting Figure.3). The ratio between the number of ligands decorating the surface of 
cancer cells and the number of receptors expressed on the endothelium is rl. Two different ratios ρl were 
considered, namely 0.3 and 0.6. These assumed ligand densities return a good agreement between the 
experimental and numerical predictions for the cell rolling velocity over three different flow rates. 
At first, cancer cells were assumed to be rigid, which is indeed the simplest possible hypothesis. Then, 
simulations were performed for estimating the rolling velocities of cancer cells over the vascular wall as 
a function of four different flow rates, namely Q = 25, 50, 75, and 100 nL/min; and two 𝜌" ratios, namely 
0.3 and 0.6. The resulting data are shown in Figure.5b (lines) where a direct comparison with the 
corresponding experimental data is also included (blue dots for HCT-15 cells). From the simulations, the 
cell rolling velocity was predicted to grow quasi-linearly with the flow rate Q (R2 = 0.998 and 0.994 for 𝜌" = 0.3 and 0.6, respectively) and slightly decrease with an increase in 𝜌" = 0.3. Overall, the predicted 
rolling velocities were found to be in good agreement with the experimental data for Q = 100 nL/min, 
returning a relative error smaller than 0.74% and 3.10% for 𝜌" = 0.3 and 0.6, respectively. A larger 
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difference was observed at low flow rates, Q = 50 nL/min, where the relative error increased to about 
43.01% and 52.07% for 𝜌" = 0.3 and 0.6, respectively. This might be due to the fact that this flow rate is 
very close to the lower limit for the syringe pump used in the experiments. Note that an increase in 𝜌" 
from 0.3 to 0.6 was associated with only a 3.5% decrease in rolling velocity. This is also in agreement 
with the experimental data of Figure.3a and b documenting a modest variation in uroll with vascular 
inflammation. 
Although the ‘rigid cell’ approximation quite accurately modeled the rolling behavior of cancer cells, it 
could not predict their firm vascular adhesion. Therefore, in a second set of simulations, the cancer cell 
was considered as a deformable capsule characterized by the dimensionless capillary number Ca = 10 -2. 
These data are plotted in Figures.5c and f for four different flow rates (Q = 25, 50, 75, and 100 nL/min); 
two ligand-receptor densities (𝜌"=0.3 and 0.6). Also, a direct comparison between rigid and soft cells is 
provided. Soft cells exhibited more complex vascular adhesion patterns. For 𝜌"=0.3, soft cells were 
observed to establish an initial adhesive contact with the endothelial surface resulting in partial cell 
deformation and increase in the number of ligand-receptor bonds. However, after reaching a maximum, 
the adhesive interactions were not sufficient to counteract the dislodging hydrodynamic forces and, 
consequently, the number of close bonds reduced tending eventually to zero. For 𝜌"=0.6, a larger number 
of ligand-receptor bonds could be formed leading to stronger adhesive interactions. This is indeed 
observed in the plots of Figure.5c and f. Also, for sufficiently high flow rates (Q ³ 50 nL/min), partially 
adhering soft cells were deformed and pushed down to the wall thus maximizing their adhesive surface 
and interface forces and leading to a 2 to 3-times higher number of ligand-receptor bonds as compared 
to the corresponding rigid cell cases (Figure.5e and f). Notably, simulations predicted that rigid cells 
would roll over the endothelium with a rolling velocity decreasing with an increasing surface density of 
ligands (black and blue lines in Figure.5c and f). Differently, deformable cells would, for low ligand 
surface densities, transiently adhere, detach and move away from the wall pushed by hydrodynamic lift 
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forces (red lines in Figure. 5c and f); whereas, for high ligand surface densities, deformable cells would 
firmly adhere, deform under flow and increase the surface of adhesion as documented by the growth of 
the number of the engaged ligand-receptor bonds. (green lines in Figure. 5c and f and Supporting 
Figure.4). Although the present simulations can quite accurately predict the rolling velocities of 
circulating cancer cells, it should be emphasized that only a fully 3D model, including deformable RBCs 
and CTCs, could realistically predict the vascular behavior of cancer cells.(Fedosov, Caswell, and 
Karniadakis 2011; Muller, Fedosov, and Gompper 2014) 
 
CONCLUSIONS 
A microfluidic chip was used to analyze the vascular transport of circulating tumor cells under different 
biophysical conditions. The surface density of adhering cells and the velocity of rolling cells were 
quantitatively characterized over a confluent endothelial monolayer as a function of the level of 
inflammation (no TNF-a; TNF-a stimulation for 6h; TNF-a stimulation for 12h); flow rate (50 and 100 
nL/min); and working fluid (physiological solution and whole blood, at 40% hematocrit). Two different 
types of cancer cells – colorectal HCT-15 and breast cancer MDA-MB-231 cells – were considered. 
It was confirmed that vascular inflammation facilitates cell adhesion in a way proportional to TNF-a 
stimulation, whereas high flow rates are associated with lower cell deposition. Rolling velocities are only 
slightly affected by vascular inflammation and grow proportionally with the flow rate. As compared to a 
physiological solution, flowing cancer cells in whole blood enhances their firm deposition on healthy 
endothelium rather than on the inflamed vasculature, for all tested conditions. No statistically significant 
difference is observed for adhesion and rolling between HCT-15 and MDA-MB-231 cells. 
These results would imply that neglecting the contribution of whole blood in the analysis of cancer cell 
dynamics can significantly underestimate their vascular deposition. Furthermore, it can be concluded that 
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whole blood flow supports cancer cell deposition and facilitates metastatization over the entire 
microvasculature. 
 
EXPERIMENTAL SECTION 
Fabrication of a single channel microfluidic chip. The single channel microfluidic chip was fabricated 
following protocols previously demonstrated by the authors.(Manneschi et al. 2016) Briefly, a SU8-50 
master was used as a mold for PDMS replicas of the chip. First a 40 µm thick layer of SU8-50 photoresist 
(MicroChem) was spin coated on a silicon wafer (4”- P doped - <100> - 10 ÷ 20 W/cm2 – 525 µm thick, 
from Si-Mat) at 2000 rpm for 30 s. Then, the negative SU8-50 template was pre-and soft baked for 
solvent evaporation; exposed to UV light and baked again for epoxy crosslinking; and finally developed. 
This template was replicated using a mixture of PDMS and curing agent Sylgard 182 (Dow Corning 
Corporation), with a ratio (w:w) 10:1. Specifically, the mixture was poured on the SU8-50 template, 
cured in an oven at 60°C for 15 h, and moved at -20°C for 1 h. After peeling off from the template, the 
channel extremities of the PDMS replica were punched via a biopsy puncher (OD = 1 mm, Miltex) to 
form inlet and outlet ports. Finally, upon oxygen plasma treatment (Pressure = 0.5 mBar, Power = 15 w, 
Time = 15 s; Plasma System Tucano, Gambetti), PDMS replica was sealed with a glass slide (20 x 60 x 
0.17 mm) (No. 1.5H, Deckaläser). The resulting microfluidic chip has a rectangular cross section with a 
width w = 210 µm, height h = 42 µm, and a port-to port length l = 2.7 cm. 
 
Seeding of endothelial cells into the microfluidic chip. Chips were sterilized by autoclave, dried and 
covered with 20 µg/mL of fibronectin to allow cell adhesion. HUVECs were introduced in the channel 
from the inlet port at a density of 3×106 cells/mL by using a pipette tip. Then, chips were placed in an 
incubator, to allow cell attachment and growth, and continuously perfused with Endothelial cell growth 
medium supplement-mix (PROMOCELL) until cell confluency was achieved. HUVEC monolayers were 
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inflamed, at the occurrence, with 25 ng/mL of TNF-α for 6 or 12 hours. Each experiment was compared 
to untreated HUVEC monolayer (-TNF-α). 
 
Cancer cell adhesion and rolling under dynamic conditions. The microfluidic chip was placed on the 
stage of an epi-fluorescence inverted microscope (Leica 6000). The working fluid was injected into the 
chip using a syringe pump 33 Dual (Harvard apparatus). After the tripsinization, the cancer cells were 
incubated for 30 minutes with CM-DIL, at 37 ˚C (0,5%, Thermofisher) according to the manufacture’s 
protocol. Then, the cells were washed 3 times with PBS 1x (GIBCO) to remove the excess dye. Finally, 
the cells were re-suspended in the RPMI medium (HCT-15) or EMEM medium (MDA-MB-231), without 
FBS, that could interfere with the cell adhesion parameters, at 1x106 cells/mL. After each rolling 
experiment, a washing with PBS was performed to remove the non-adherent cancer cells from the 
endothelium. Tumor cells were introduced via a syringe pump on the HUVEC monolayer inside the 
single channel chip. The inlet port of the chip was connected to the syringe pump through a polyethylene 
tube (BTPE-60, Instech Laboratories), while the tube of the outlet port was in PBS, to ensure flow 
equilibrium. After 1 minute of flow, the interaction of tumor cells with HUVECs was recorded for 15 
consecutive minutes for each experiment. Two flow rates Q were imposed via the syringe pump, namely 
50 and 100 nL/min. The resulting rolling velocity of tumor cells was calculated offline by post processing 
the videos, using the distance traveled by the cell and divided by the time, within a region of interest 
(ROI) (magnification 10 X, A = 1.22 X 10-6 m2). At least 15 cancer cells per experiment were monitored. 
Each experiment was repeated three times for each different conditions and flow rates. For the study of 
cell adhesion under whole blood flow, the working fluid was obtained by combining a cancer cell 
suspension (density of 106 cells/mL) with whole blood from rat, collected in a standard blood test tubing 
containing 3.2% of buffered citrate to prevent clotting. The working hematocrit was fixed to 40%. 
Experiments and image acquisition were performed as described above.  
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SUPPLEMENTARY MATERIALS 
See supplementary material for the complete description of the materials and methods used in the cell 
culturing; CTCs adhesion measurement in static and dynamic conditions; and computational modelling. 
Supplementary material include also supporting figures and movies about CTCs adhesion and rolling on 
inflamed endothelium, the computed adhesion mechanics of deformable cells, and confocal microscopy 
images of the adhesion molecules in the microfluidic chip.  
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FIGURES AND GRAPHICS 
 
 
Figure 1. Single-channel microfluidic chip. a. On the left, schematic representation of a single channel 
microfluidic chip with length l = 2.7 cm, width w = 210 µm; height h = 42 µm. On the right, a single 
channel microfluidic chip, with connecting inlet and outlet tubing, filled with a blue ink and placed on 
the stage of a fluorescent inverted microscope. b. Representative confocal fluorescent microscopy images 
of HCT-15 cells (membrane labeled in red with CM-DIL) flowing in the chip and interacting with a 
confluent layer of HUVECs (nuclei stained in blue with DAPI). VE-cadherin adhesion molecules, arising 
at boundaries of the endothelial cells, are stained in green. (Images are provided for unstimulated (-TNF-
α) and TNF-α stimulated HUVECs for 6 (+ TNF-α 6h) and 12 hours (+ TNF-α 12h). TNF-α 
concentration: 25 ng/mL. Scale bar: 50 µm). 
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Figure 2. Cancer cell adhesion on inflamed endothelial cells under dynamic conditions. a. 
Representative fluorescence microscopy images of breast cancer cells MDA-MB-231 (cell membrane 
labeled in red with CM-DIL) flowing and interacting, in a single-channel microfluidic chip, with a 
confluent monolayer of HUVECs (cell nuclei stained in blue with DAPI). b. Normalized number of 
adhering cancer cells on a HUVEC monolayer at a flow rate of 50 nL/min, with and without stimulation 
with TNF-α (25ng/mL), for 6 and 12 hours. c. Representative fluorescence microscopy images of colon 
cancer cells HCT-15 (cell membrane labeled in red with CM-DIL) flowing and interacting, in a single-
channel microfluidic chip, with a confluent monolayer of HUVECs (cell nuclei stained in blue with 
DAPI). d. Normalized number of adhering cancer cells on a HUVEC monolayer at a flow rate of 100 
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nL/min, with and without stimulation with TNF-α (25ng/mL), for 6 and 12 hours. (Data are plotted as 
mean ± SD. n = 3. Statistical analysis ANOVA: *** symbol denotes statistically significant difference 
p < 0.0001; ** symbol denotes statistically significant difference p < 0.001. (ninj=10
6 cells and A = 
1.22´10-6 m2). HUVECs are not stimulated with TNF-α (-TNF-α) or stimulated with 25 ng/mL TNF-α 
for 6h (+TNF-α 6h) or 12h (+TNF-α 12h)). 
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Figure 3. Cancer cell rolling on inflamed endothelial cells under dynamic conditions. (.a,.b) Rolling 
velocity of colon cancer HCT-15 (red column) and breast cancer MDA-MB-231 (blue column) at 50 
nL/min and 100 nL/min on a confluent layer of HUVEC. (.c,.d) Ratio between the number of rolling and 
adhering cancer cells (HCT-15 - red column; breast cancer MDA-MB-231 - blue column) on a confluent 
layer of HUVEC at 50 nL/min and 100 nL/min. HUVECs are not stimulated with TNF-α (-TNF-α) or 
stimulated with 25 ng/mL of TNF-α for 6h (+TNF-α 6h) or 12h (+TNF-α 12h). (Data are plotted as mean ± SD. n = 3. Statistical analysis ANOVA. * symbol denotes statistically significant difference p<0.01; 
** symbol denotes statistically significant difference p<0.001; *** symbol denotes statistically 
significant difference p<0.0001).  
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Figure 4. Cancer cell adhesion on inflamed endothelial cells under whole blood flow. a. 
Representative fluorescence microscopy images of breast cancer cells MDA-MB-231 (cell membrane 
labeled in red with CM-DIL) flowing in whole blood and interacting, in a single-channel microfluidic 
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chip, with a confluent monolayer of HUVECs (cell nuclei stained in blue with DAPI). b. Normalized 
number of adhering cancer cells on a HUVEC monolayer of colon cancer HCT-15 (red column) and 
breast cancer MDA-MB-231 (blue column) at a flow rate (50 nL/min), with and without stimulation with 
TNF-α (25ng/mL) in the presence of whole blood (hematocrit: 40%). c. Representative fluorescence 
microscopy images of colon cancer cells HCT-15 (cell membrane labeled in red with CM-DIL) flowing 
in whole blood interacting, in a single-channel microfluidic chip, with a confluent monolayer of 
HUVECs (cell nuclei stained in blue with DAPI). d. Normalized number of adhering cancer cells on a 
HUVEC monolayer of colon cancer HCT-15 (red column) and breast cancer MDA-MB-231 (blue 
column) at high flow rate (100 nL/min), with and without stimulation with TNF-α (25ng/mL) in the 
presence of whole blood (hematocrit: 40%). (e.,.f.) Normalized number of adhering colon cancer HCT-
15 (red column) and breast cancer MDA-MB-231 (blue column) on a HUVEC monolayer, without (f.) 
and with (e.) stimulation of TNF-α (25ng/mL) for 12h at a flow rate of 50 nL/min and 100 nL/min, with 
and without whole blood (hematocrit: 40%). (Data are plotted as mean ± SD. n = 3. Statistical analysis 
ANOVA: * symbol denotes statistically significant difference p < 0.05; ** symbol denotes statistically 
significant difference p < 0.01 (ninj = 106 cells and A = 1.22´10-6 m2)). 
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Figure 5. Predicting cancer cell adhesion and rolling on inflamed endothelial cells.  a. Schematic 
diagram presenting the computational problem with a close-up depicting ligand-receptor interactions at 
the interface between cancer (up) and endothelial (lower) cells. b. Rolling velocities of cancer cells under 
four different flow rates (Q = 25, 50, 75, and 100 nL/min) and two ligand-receptor bond concentrations 
(𝜌" = 0.3 and 0.6). (Solid lines are simulated values; Dots are experimental values; dashed lines are 
theoretical values). c, d, e, f. Variation of the number of active ligand-receptor bonds over time, under 
four different flow rates (Q = 25, 50, 75, and 100 nL/min), two ligand-receptor bond concentrations (𝜌" 
31 
 
= 0.3 and 0.6), and for soft and rigid cancer cells. Nl is the number of closed bonds in each time step. 
This number is computed as the ratio between the current number of closed bonds over the number of 
closed bonds in the initial configuration.” 
 
